Loading clinical trials...

Impact of a European Training Program for Robotic Liver Surgery (LIVEROBOT) | Clinical Trials | Clareo Health

UNKNOWN

Impact of a European Training Program for Robotic Liver Surgery (LIVEROBOT)

NCT05723705•Amsterdam UMC, location VUmc

Summary

LIVEROBOT is a collaboration of high-volume liver surgical centers in Europe (≥60 liver resections per year), supported by the European-African Hepato-Pancreato-Biliary Association Education Committee (E-AHPBA), and the European Registry of Minimally Invasive Liver Surgery (E-MILS) aiming to support the step-up implementation and safety of advanced surgical expertise of robotic liver surgery (RLS) on a European basis. The LIVEROBOT training program aims to promote the safe implementation of RLS throughout Europe. The data from all patients operated on during a surgeons' participation in the training program will be prospectively gathered allowing for learning curve and outcome analyses.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Center/Surgeon Eligibility Criteria:
•Prior to admission to the LIVEROBOT training program surgeons must demonstrate laparoscopic experience with a laparoscopic cholecystectomy with OSATS score \>3 (reviewed by proctors), participation in the LAELIVE training program or demonstrating more than two-year experience in clinical laparoscopic liver surgery. Additionally, a minimal surgical volume is required for participation. Annual liver surgery volume (open and minimally invasive combined) per two surgeons should be more 60, aiming to reach more than 40 RLS annually. Each participating surgeon should individually perform a minimum of more than 15 hepatectomy procedures annually. Surgeons shall be excluded from the training program if at any point failing to meet the minimal volume criteria (corrected for COVID-19 restrictions).
•Age equal or above 18 years
•Eligible for elective minimally invasive and open hepatectomy for malignant, pre-malignant or benign disease located in the liver or biliary tract
•Eligible for both minimally invasive and open surgery according to the operating surgeon
•Fit to undergo the indicated operation according to both the anaesthesiologist and surgeon

Exclusion Criteria

•Pregnancy

Key Dates

Start Date

April 1, 2023

Primary Completion Date

December 1, 2025

Completion Date

December 1, 2025

Last Updated

March 27, 2023

Enrollment

3,600

ESTIMATED participants

Conditions

Liver DiseasesLiver NeoplasmLiver CancerLiver MetastasesBiliary Tract CancerBiliary Tract NeoplasmsBiliary Tract Diseases

Interventions

European Multicentre Training Program for Robotic Liver Surgery

OTHER

Contacts

Gabriela Pilz da Cunha, MD

CONTACT

020 444 4444 g.pilzdacunha@amsterdamumc.nl

Early Detection of Liver Cancer by QUS

NCT06345508

Hepatocellular CarcinomaLiver Cancer

View study

RECRUITINGPHASE2

Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial

NCT07447050

Breast CancerSarcoma+8 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 27, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Impact of a European Training Program for Robotic Liver Surgery (LIVEROBOT)

Inclusion Criteria

Exclusion Criteria

Early Detection of Liver Cancer by QUS

Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial

A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors

Cancer Loyalty Card Study 2 (CLOCS-2)

MAsS Scan as a Predictor of Morbidity and Mortality in Patients With Liver Disease

Translation of Acoustic Angiography: Contrast Enhanced Super Resolution (CESR) Imaging